Dr. Edward Garon on the Future of Combination Treatments in Lung Cancer

December 4, 2015
Edward Garon, MD

Garon says the likely place to start when looking into combination therapies are cytotoxic chemotherapy and tyrosine kinase inhibitors, given these treatments are currently approved in lung cancer.

Edward Garon, MD, assistant professor of Medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at University of California, Los Angeles, discusses the future of combination therapies in lung cancer. Garon says the likely place to start when looking into combination therapies are cytotoxic chemotherapy and tyrosine kinase inhibitors, given these treatments are currently approved in lung cancer.

Garon says that some immunotherapies are in early phase trials for the treatmnet of lung cancer. CTLA-4 inhibitors, popular in melanoma treatment, may also play a role in lung cancer treatment along with the inhibition of the PD-1 checkpoint, says Garon. He adds that he is hopeful that these therapies will be effective in treating lung cancer, though he is concerned about the potential toxicities that may come along with them.